These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28951193)

  • 1. Impact of Toxicity on Survival for Older Adult Patients after CD34
    Shah GL; Scordo M; Kosuri S; Herrera DA; Cho C; Devlin SM; Borrill T; Carlow DC; Avecilla ST; Meagher RC; O'Reilly RJ; Jakubowski AA; Papadopoulos EB; Koehne G; Gyurkocza B; Castro-Malaspina H; Shaffer BC; Perales MA; Giralt SA; Tamari R
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):142-149. PubMed ID: 28951193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34
    Scordo M; Shah GL; Kosuri S; Herrera DA; Cho C; Devlin SM; Maloy MA; Nieves J; Borrill T; Avecilla ST; Meagher RC; Carlow DC; O'Reilly RJ; Papadopoulos EB; Jakubowski AA; Koehne G; Gyurkocza B; Castro-Malaspina H; Tamari R; Perales MA; Giralt SA; Shaffer BC
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):133-141. PubMed ID: 28870777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.
    Rondon-Clavo C; Scordo M; Hilden P; Shah GL; Cho C; Maloy MA; Papadopoulos EB; Jakubowski AA; O'Reilly RJ; Gyurkocza B; Castro-Malaspina H; Tamari R; Shaffer BC; Perales MA; Jaimes EA; Giralt SA
    Biol Blood Marrow Transplant; 2018 Dec; 24(12):2517-2522. PubMed ID: 30055353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34
    Kosuri S; Adrianzen Herrera D; Scordo M; Shah GL; Cho C; Devlin SM; Maloy MA; Nieves J; Borrill T; Carlow DC; Avecilla ST; Meagher RC; O'Reilly RJ; Papadopoulos EB; Jakubowski AA; Koehne G; Gyurkocza B; Castro-Malaspina H; Shaffer BC; Tamari R; Giralt SA; Perales MA
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):2004-2011. PubMed ID: 28733264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
    Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
    Cho C; Hsu M; Barba P; Maloy MA; Avecilla ST; Barker JN; Castro-Malaspina H; Giralt SA; Jakubowski AA; Koehne G; Meagher RC; O'Reilly RJ; Papadopoulos EB; Ponce DM; Tamari R; van den Brink MRM; Young JW; Devlin SM; Perales MA
    Bone Marrow Transplant; 2017 Dec; 52(12):1629-1636. PubMed ID: 28991247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34
    Scordo M; Bhatt V; Hilden P; Smith M; Thoren K; Cho C; Shah GL; Maloy MA; Papadopoulos EB; Jakubowski AA; Avecilla ST; O'Reilly RJ; Castro-Malaspina H; Tamari R; Shaffer BC; Boelens JJ; Perales MA; Giralt SA
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1526-1535. PubMed ID: 30831208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
    Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.
    Malard F; Labopin M; Cho C; Blaise D; Papadopoulos EB; Passweg J; O'Reilly R; Forcade E; Maloy M; Volin L; Castro-Malaspina H; Hicheri Y; Jakubowski AA; Orvain C; Giralt S; Mohty M; Nagler A; Perales MA
    J Hematol Oncol; 2018 Oct; 11(1):127. PubMed ID: 30342553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex Vivo CD34
    Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts.
    Jacob RP; Flynn J; Devlin SM; Maloy M; Giralt SA; Maslak P; O'Reilly RJ; Tonon JA; Perales MA; Avecilla ST; Cho C
    Transplant Cell Ther; 2021 Aug; 27(8):697.e1-697.e5. PubMed ID: 33991721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
    Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
    Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
    Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.
    Scordo M; Hsu M; Jakubowski AA; Shah GL; Cho C; Maloy MA; Avecilla ST; Papadopoulos EB; Gyurkocza B; Castro-Malaspina H; Tamari R; O'Reilly RJ; Perales MA; Giralt SA; Shaffer BC
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1136-1141. PubMed ID: 30625387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation.
    Nawas MT; Sanchez-Escamilla M; Devlin SM; Maloy MA; Ruiz JD; Sauter CS; Giralt SA; Perales MA; Scordo M
    Blood Adv; 2022 Nov; 6(22):5898-5907. PubMed ID: 35977079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
    Nakaya A; Mori T; Tanaka M; Tomita N; Nakaseko C; Yano S; Fujisawa S; Sakamaki H; Aotsuka N; Yokota A; Kanda Y; Sakura T; Nanya Y; Saitoh T; Kanamori H; Takahashi S; Okamoto S
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1553-9. PubMed ID: 25034961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.
    Keller JW; Andreadis C; Damon LE; Kaplan LD; Martin TG; Wolf JL; Ai WZ; Venstrom JM; Smith CC; Gaensler KM; Hwang J; Olin RL
    J Geriatr Oncol; 2014 Jul; 5(3):238-44. PubMed ID: 24894413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation.
    Berro M; Arbelbide JA; Rivas MM; Basquiera AL; Ferini G; Vitriu A; Foncuberta C; Fernandez Escobar N; Requejo A; Milovic V; Yantorno S; Szelagoswki M; Martinez Rolon J; Bentolila G; Garcia JJ; Garcia P; Caeiro G; Castro M; Jaimovich G; Palmer S; Trucco JI; Bet LA; Shaw BE; Kusminsky GD
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1646-1650. PubMed ID: 28669923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.